# Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

Study · id `cardio:ct-nct04853758` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04853758](<https://clinicaltrials.gov/study/NCT04853758>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04853758

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04853758. Randomized; triple masking; primary purpose treatment. Start 2021-05-06 (actual); primary completion 2024-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04853758, source copy `cardio:ctgov-nct04853758-2024-04-04`, retrieved 2026-10-26)
- Started: 2021-05-06 (actual) (ClinicalTrials.gov record NCT04853758, source copy `cardio:ctgov-nct04853758-2024-04-04`, retrieved 2026-10-26)
- Primary completion: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT04853758, source copy `cardio:ctgov-nct04853758-2024-04-04`, retrieved 2026-10-26)
- Completion: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT04853758, source copy `cardio:ctgov-nct04853758-2024-04-04`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT04853758, source copy `cardio:ctgov-nct04853758-2024-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04853758-2024-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Acronym: ANSWER-HF
- Condition: Chagas Cardiomyopathy
- Intervention (Drug): Sacubitril / Valsartan Oral Tablet \[Entresto\]
- Intervention (Drug): Enalapril
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER
- Collaborator: InCor Heart Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)
- Registry lists this organization as a collaborator: InCor Heart Institute (`cardio:org-incor-heart-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial (`cardio:pubmed-41396086`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c1c780a87c17d03ef66d10f735d1e37abc0c9c1ce02d8dc26fe37c1f33f2e2bf
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
